<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562389</url>
  </required_header>
  <id_info>
    <org_study_id>XPORT-MF-034</org_study_id>
    <secondary_id>2020-003883-19</secondary_id>
    <nct_id>NCT04562389</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate Safety and Efficacy of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib, in Treatment Naïve Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global, Phase 1/2, multicenter, open-label study to evaluate the safety and&#xD;
      efficacy of selinexor plus ruxolitinib in treatment naïve myelofibrosis (MF) participants.&#xD;
      The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study&#xD;
      will be dose escalation (non-randomized dose finding study) to determine the maximum&#xD;
      tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary&#xD;
      efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose&#xD;
      expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the&#xD;
      safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy&#xD;
      exploration) of the study will include MF participants who are treatment naïve randomized 1:1&#xD;
      to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Approximately within the first cycle (28 days) of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approximately within the first cycle (28 days) of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity</measure>
    <time_frame>From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Percentage of Participants who will Achieve Spleen Volume Reduction of at least 35 percentage (%) (SVR35): Assessment by Independent Review Committee (IRC)</measure>
    <time_frame>Baseline up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who will Achieve Total Symptom Score Reduction Greater Than or Equal to (≥) 50% (TSS50) as Measured by Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): Assessment by IRC</measure>
    <time_frame>Baseline up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who will Achieve Spleen Volume Reduction of at least 25% (SVR25): Assessment by IRC</measure>
    <time_frame>Baseline up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 12 months after last dose of study treatment (approximately 60 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaemia Response: Assessment by IRC</measure>
    <time_frame>Baseline up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AEs by Occurrence, Nature, and Severity</measure>
    <time_frame>From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SVR35</measure>
    <time_frame>Baseline up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SVR25</measure>
    <time_frame>Baseline up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of TSS50</measure>
    <time_frame>Baseline up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Cycle 1 Day 1 (28-day cycle) up to 28 days after last dose of study treatment (approximately 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and Cycle 1 Day 16 (28-day cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Concentration-time Curve (AUC)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and Cycle 1 Day 16 (28-day cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and Cycle 1 Day 16 (28-day cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Area Under the Concentration-time Curve (AUC)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and Cycle 1 Day 16 (28-day cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MF will receive a dose of 40 milligrams (mg) of selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg twice a day (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MF will receive a dose of 60 mg of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MF will receive a dose of 20 mg of selinexor oral tablet twice weekly (BIW) of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MF will receive recommended safe dose (estimated in Phase 1a) of selinexor oral tablets on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MF will receive recommended safe dose (estimated in Phase 1b) of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with MF will receive ruxolitinib oral tablets 15 or 20 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Formulation: 20 mg Tablet; Dose: 20, 40 (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg); Route of Administration: Oral</description>
    <arm_group_label>Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Formulation: 5, 10 mg Tablet; Dose: 15, 20 mg; Route of Administration: Oral</description>
    <arm_group_label>Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 2: Ruxolitinib 15/20 mg</arm_group_label>
    <arm_group_label>Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary MF or post-essential thrombocythemic or post-polycythemia&#xD;
             according to the 2016 world health organization (WHO) classification of MPN confirmed&#xD;
             by the most recent local pathology report.&#xD;
&#xD;
          -  Measurable splenomegaly during the screening period as demonstrated by spleen volume&#xD;
             of ≥450 cubic centimeter (cm^3) by MRI or CT-scan.&#xD;
&#xD;
          -  Participants with dynamic international prognostic scoring system (DIPSS) risk&#xD;
             category of intermediate-1, intermediate-2, or high-risk.&#xD;
&#xD;
          -  Participants ≥18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to&#xD;
             (≤) 2.&#xD;
&#xD;
          -  Platelet count ≥100 * 10^9/Liter (L).&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5 * 10^9/L.&#xD;
&#xD;
          -  Serum direct bilirubin ≤1.5 * upper limit of normal (ULN); Aspartate transaminase&#xD;
             (AST) and alanine transaminase (ALT) ≤2.5 * ULN.&#xD;
&#xD;
          -  Creatinine clearance (CrCl) greater than (&gt;) 15 milliliters per minute (mL/min) based&#xD;
             on the Cockcroft and Gault formula.&#xD;
&#xD;
          -  Participants with active hepatitis B virus (HBV) are eligible if antiviral therapy for&#xD;
             hepatitis B has been given for &gt;8 weeks and viral load is less than (&lt;) 100&#xD;
             international units/milliliter (IU/mL).&#xD;
&#xD;
          -  Participants with untreated hepatitis C virus (HCV) are eligible there is&#xD;
             documentation of negative viral load per institutional standard.&#xD;
&#xD;
          -  Participants with history of human immunodeficiency virus (HIV), are eligible if&#xD;
             participants have cluster of differentiation 4 (CD4)+ T-cell counts ≥350&#xD;
             cells/microliter, negative viral load per institutional standard, and no history of&#xD;
             acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the&#xD;
             last year.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum pregnancy&#xD;
             test at screening and agree to use highly effective methods of contraception&#xD;
             throughout the study and for one month following the last dose of study treatment.&#xD;
             Childbearing potential excludes: Age &gt;50 years and naturally amenorrhoeic for &gt;1 year,&#xD;
             or previous bilateral salpingo-oophorectomy, or hysterectomy.&#xD;
&#xD;
          -  Male participants who are sexually active must use highly effective methods of&#xD;
             contraception throughout the study and for one month following the last dose of study&#xD;
             treatment. Must agree not to donate sperm during the study treatment period.&#xD;
&#xD;
          -  Participants must sign the written informed consent in accordance with federal, local&#xD;
             and institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt;5% blasts in peripheral blood or &gt;10% blasts in bone marrow (accelerated phase).&#xD;
&#xD;
          -  Received previous treatment with Janus kinase (JAK) inhibitors for MF (treatment with&#xD;
             hydroxyurea for up to 2 weeks is allowed).&#xD;
&#xD;
          -  Previous treatment with selinexor or other exportin-1 (XPO1) inhibitors.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that could significantly&#xD;
             alter the absorption of selinexor.&#xD;
&#xD;
          -  Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to selinexor&#xD;
             dosing or strong CYP3A inducers ≤14 days prior to selinexor dosing.&#xD;
&#xD;
          -  Major surgery &lt;28 days prior to cycle 1 day 1 (C1D1).&#xD;
&#xD;
          -  Uncontrolled (i.e. clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals within 7 days prior to first dose of study treatment;&#xD;
             however, prophylactic use of these agents is acceptable (including parenteral).&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the Investigator's opinion, could compromise the patient's safety, prevent the patient&#xD;
             from giving informed consent, or being compliant with the study procedures.&#xD;
&#xD;
          -  Female participants who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jatin Shah, Chief Medical Officer, MD</last_name>
    <phone>(617) 658-0600</phone>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, President and Chief Scientific Officer, PhD, MBA</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haris Ali, MD</last_name>
      <phone>626-356-4673</phone>
      <email>harisali@coh.org</email>
    </contact>
    <investigator>
      <last_name>Haris Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope &amp; Innovation</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitabha Mazumder</last_name>
      <phone>562-693-4477</phone>
      <email>amazumder@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Amitabha Mazumder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Mohan, MD</last_name>
      <phone>615-936-8422</phone>
      <email>sanjay.mohan@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Mohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinivas Tantravahi</last_name>
      <phone>801-213-6170</phone>
      <email>Srinivas.Tantravahi@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Srinivas Tantravahi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keri Maher, DO</last_name>
      <phone>760-954-3800</phone>
      <email>Keri.Maher@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Keri Maher, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Selinexor</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>Janus kinase 2</keyword>
  <keyword>Myeloproliferative neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

